Drug
BPN14770 clinical trials
Also written BPN14770 and Zatolmilast.
- studies test it
- 14
- open now
- 0
- in phase 3
- 3
- first study started
- 2015
How studies write it
Studies that test it under each name
Development codes
- BPN14770
- 11
Other names
Studies by the year they started
14 studies that test it; most in 2025 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2022 | 3 |
| 2025 | 4 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 13 · Other 1
Tetra Discovery Partners (9) · Shionogi (4) · National Institute of Mental Health (NIMH) (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses BPN14770 is read from its arms, and is right about nine times in ten.
Testing it · 14
- A Randomized Study of BPN14770 in Male Adolescents (Aged 9 to < 18 Years) With Fragile X SyndromeCompletedPhase 2/3Tetra Discovery PartnersNCT05163808Written as zatolmilast
- A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X SyndromeCompletedPhase 3Tetra Discovery PartnersNCT05358886Written as BPN14770/ zatolmilast
- Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])Active, not recruitingPhase 2ShionogiNCT06717438Written as BPN14770
- Phase 1 Study of BPN14770 in Participants With Hepatic Impairment and Healthy ControlsCompletedPhase 1ShionogiNCT07018492Written as BPN14770
- Study of BPN14770 in Participants With Severe Renal Impairment and Healthy ControlsCompletedPhase 1ShionogiNCT07012005Written as BPN14770
- An Open-Label Extension Study of BPN14770 in Subjects With Fragile X SyndromeActive, not recruitingPhase 3Tetra Discovery PartnersNCT05367960Written as Zatolmilast/ BPN14770
- A Study to Assess the Effects of BPN14770 on RosuvastatinCompletedPhase 1ShionogiNCT07011992Written as BPN14770
- Tetra PICASSO AD Trial: Study to Evaluate Effects of BPN14770 in Early Alzheimer's SubjectsCompletedPhase 2Tetra Discovery PartnersNCT03817684Written as BPN14770
- A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X SyndromeCompletedPhase 2Tetra Discovery PartnersNCT03569631Written as BPN14770
- A Phase 1, Open-Label, PET Study of T2310 & BPN14770WithdrawnPhase 1Tetra Discovery PartnersNCT04044781Written as BPN14770, T2310
- Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)CompletedPhase 1/2National Institute of Mental Health (NIMH)NCT03861000Written as BPN14770
- Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy VolunteersCompletedPhase 1Tetra Discovery PartnersNCT03030105Written as BPN14770
- BPN14770 Single Ascending Dose Study in Healthy Male and Female SubjectsCompletedPhase 1Tetra Discovery PartnersNCT02648672Written as BPN14770
- A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female SubjectsCompletedPhase 1Tetra Discovery PartnersNCT02840279Written as BPN14770
Codes
What other systems call BPN14770 · ClinicalTrials.gg INT001936
- MeSH (NLM) C000723101BPN14770One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000723101 | BPN14770 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.